* Prestige Consumer Healthcare Inc PBH.N PBH is expected
to show a fall in quarterly revenue when it reports results on
November 2.
* The Tarrytown New York-based company is expected to
report a
0.7% decrease in revenue to $285.213 million from $287.27
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. The company's guidance on
August 3 2023, for the period ended September 30, was for
revenue of $285.000 million.
* Refinitiv's mean analyst estimate for Prestige Consumer
Healthcare Inc is for earnings of $1.07 per share. The company's
EPS guidance on August 3 2023, for the period ended September
30, was about USD1.07
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Prestige
Consumer
Healthcare Inc is $72, above its last closing price of $58.92.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 1.01 1.01 1.06 Beat 5
Mar. 31 2023 1.04 1.04 -4.83 Missed -564.4
Dec. 31 2022 1.01 1.01 1.04 Beat 2.6
Sep. 30 2022 1.00 1.00 1.02 Beat 1.8
Jun. 1.04 1.04 1.09 Beat 5
30 2022
Mar. 31 2022 0.89 0.89 0.91 Beat 2.6
Dec. 31 2021 0.88 0.88 0.99 Beat 12.1
Sep. 30 2021 0.99 0.99 1.02 Beat 3.4
This summary was machine generated October 31 at 19:00 GMT. All
figures in US dollars unless otherwise stated